CHMP recommends EU conditional approval of Roche's antibody Mosunetuzumab for people with relapsed Follicular Lymphoma - Express Pharma
Raul Cordoba, MD, PhD on Twitter: "#ASH19 Mosunetuzumab induces CR in poor prognosis NHL patients including those who are resistant to or relapsing after #CART therapies #lymsm. Data coming from the first
Ash 2019 – Roche doesn't disappoint with bispecific | Evaluate
Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study -
PDF) An individualized risk mitigation approach for safety: experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk.
ASH 2022: Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Roche eyes year-end Lunsumio FDA bispecific verdict in lymphoma
CHMP backs Roche's lymphoma bispecific mosunetuzumab | pharmaphorum
EU first to clear Roche's lymphoma bispecific mosunetuzumab | pharmaphorum
ASH 2022: Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma
Roche antibody posts strong tumor responses in lymphoma study
Roche presents new data from its bispecific antibody
IJMS | Free Full-Text | Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts | Fierce Biotech
LUNSUMIO™ (mosunetuzumab-axgb) for third-line or later follicular lymphoma | HCP
Mosunetuzumab: First Approval
Industry News_Shanghai Jiaoze Industrial Co., Ltd.
Roche presents latest advances with immunotherapies in non-Hodgkin lym
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study - The Lancet Oncology
Mosunetuzumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
:quality(90)/ "Roche | Lunsumio (mosunetuzumab)")
Roche | Lunsumio (mosunetuzumab)
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Antibodies | Free Full-Text | The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study - The Lancet Oncology
Robust clinical data on Roche 3 bispecific antibodies was released- Mosunetuzumab, Glofitamab, and Cevostamab! : r/medical_trend
PATIENTENPASS
European Commission approves Roche's first-in-class
